LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a "hold" to a "sell" rating. This follows a similar downgrade by Weiss Ratings, although the consensus among analysts still rates the stock as a "Moderate Buy" with an average target price of $56.40. The article also details the company's stock performance, institutional investor holdings, and company profile.
LENZ Therapeutics, Inc. $LENZ Shares Acquired by Skandinaviska Enskilda Banken AB publ
Skandinaviska Enskilda Banken AB (publ) significantly increased its stake in LENZ Therapeutics by 99.0% in the third quarter, now holding 185,642 shares valued at approximately $8.65 million. Other institutional investors like Sovran Advisors, Saturn V, Stempoint, Geode, and Candriam also either increased or initiated positions in the company, bringing total institutional ownership to 54.32%. Despite positive analyst ratings with a "Moderate Buy" consensus and an average price target of $56.40, LENZ Therapeutics shares opened down about 2.1% at $12.77.
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Decreases By 16.8%
LENZ Therapeutics (NASDAQ:LENZ) saw a 16.8% decrease in short interest, bringing the total shorted shares to 7,260,872 as of January 30th. This translates to a days-to-cover ratio of 5.5 days and means 24.9% of the stock's shares are sold short. Despite the reduced short positioning, LENZ shares traded down 0.7% to $12.88, near its one-year low, while analysts maintain a "Moderate Buy" rating with a consensus price target of $56.40, and institutional ownership stands at approximately 54.3%.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages
LENZ Therapeutics (NASDAQ:LENZ) has received a "Moderate Buy" rating from brokerages, with an average 12-month price target of $56.40. Corporate insiders, including the CFO and a director, increased their holdings in November. Despite the "Moderate Buy" rating, the company is currently loss-making with a reported P/E of -6.93 and analysts forecast continued negative earnings.
Lenz Therapeutics price target lowered to $35 from $52 at BofA
BofA has lowered its price target for Lenz Therapeutics (LENZ) to $35 from $52, while maintaining a Buy rating. This adjustment reflects a revised model incorporating Q4 net product revenue and early Vizz script trends, leading to a 25% reduction in the 2027-32 Vizz forecast due to an anticipated slower launch. Despite the lowered forecast, BofA remains optimistic that a recently initiated direct-to-consumer ad campaign will accelerate Vizz's uptake.
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp
BofA Securities has lowered its price target for LENZ Therapeutics (NASDAQ:LENZ) to $35 from $52, while maintaining a Buy rating. This adjustment comes despite LENZ's preliminary Q4 net product revenue of $1.6 million for its presbyopia treatment Vizz exceeding consensus, as it indicated a slower-than-expected market ramp. The firm reduced its peak sales outlook for Vizz to $770 million from $840 million but remains optimistic, citing the product's effectiveness and an initiated direct-to-consumer advertising campaign.
LENZ Therapeutics and Sarah Jessica Parker Launch ‘Make it VIZZable’ Campaign
LENZ Therapeutics has launched its 'Make it VIZZable' consumer campaign for VIZZ 1.44 percent, featuring Sarah Jessica Parker as a brand ambassador. Parker, who experiences age-related blurry near vision, shares her positive experience with VIZZ, highlighting how it has improved her daily life by reducing the need for reading glasses. The campaign emphasizes VIZZ's ability to provide clear near vision without a myopic shift, with clinical trials showing significant improvement for most users within a short time frame.
In first celebrity partnership, Lenz Therapeutics taps Sarah Jessica Parker for vision campaign
Lenz Therapeutics has launched its first celebrity partnership, enlisting Sarah Jessica Parker as a brand ambassador for its new "Make It VIZZable" campaign. The campaign promotes Vizz, an FDA-approved aceclidine-based eye drop for age-related blurry vision (presbyopia), targeting the over-40 demographic. Parker shares her personal experience with presbyopia and using Vizz, aiming to raise awareness for the condition and the product, and encouraging eye doctor visits.
Sovran Advisors LLC Has $4.98 Million Stock Holdings in LENZ Therapeutics, Inc. $LENZ
Sovran Advisors LLC significantly increased its stake in LENZ Therapeutics, Inc. by 164.5% in Q3, now owning 106,920 shares valued at $4.98 million. Insider activity shows Director James W. McCollum buying shares while insider Shawn Olsson sold a portion of his holdings, reducing his ownership by nearly 68%. LENZ Therapeutics holds a "Moderate Buy" consensus rating with a target price of $56.40, and recently surpassed its EPS and revenue estimates, trading around $20.44.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP has launched an investigation into LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of its investors. This follows a significant drop in LENZ's stock price after a retinal tear case associated with its VIZZ eye drop appeared in the FDA's adverse event reporting systems. The law firm is investigating potential securities fraud or unlawful business practices by LENZ's officers and directors.
LENZ Therapeutics and Sarah Jessica Parker Launch ‘Make it VIZZable’ Campaign
LENZ Therapeutics has launched its 'Make it VIZZable' consumer campaign for VIZZ 1.44 percent, featuring Sarah Jessica Parker as brand ambassador. Parker will share her personal experience with age-related blurry near vision and how VIZZ has made a significant difference in her daily life. The campaign highlights VIZZ as a revolutionary solution to reduce reliance on reading glasses, supported by clinical trials showing extended depth of focus and improved near vision for a majority of participants.
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 9.5% - Should You Buy?
LENZ Therapeutics (NASDAQ:LENZ) saw its shares increase by 9.5% to $18.17, with trading volume significantly below average. Analysts offer a "Moderate Buy" consensus with an average target price of $56.40, and the company recently surpassed quarterly earnings and revenue estimates. Insider transactions also show purchases by a director and the CFO, indicating confidence in the company.
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign
LENZ Therapeutics has launched its "Make it VIZZable" consumer campaign for VIZZ (aceclidine ophthalmic solution) 1.44%, a once-daily eye drop that restores near vision for up to 10 hours and is an alternative to reading glasses. The campaign features actress Sarah Jessica Parker as a brand ambassador, who shares her personal experience with age-related blurry near vision and how VIZZ has improved her daily life. VIZZ is available nationwide by prescription, targeting the 128 million Americans affected by presbyopia.
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
LENZ Therapeutics has launched its "Make it VIZZable" consumer campaign for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop designed to restore near vision for up to 10 hours and serve as an alternative to reading glasses. The campaign features Sarah Jessica Parker as a brand ambassador, sharing her personal experience with age-related blurry near vision and how VIZZ has improved her daily life. VIZZ is available nationwide by prescription, targeting the 128 million Americans affected by presbyopia.
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
LENZ Therapeutics has launched its "Make it VIZZable" consumer campaign for VIZZ™ (aceclidine ophthalmic solution) 1.44%, a once-daily eye drop that restores near vision for up to 10 hours. Actress Sarah Jessica Parker is the brand ambassador, sharing her personal experience with age-related blurry near vision and how VIZZ has provided a solution, eliminating the need for reading glasses. The campaign aims to highlight the convenience and freedom VIZZ offers to the millions of Americans affected by presbyopia.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Moderate Buy" by Brokerages
LENZ Therapeutics (NASDAQ:LENZ) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month target price of $56.40. Recent insider transactions show a director buying shares while another insider sold some. The company recently reported better-than-expected quarterly earnings and revenue, though full-year EPS is still projected to be negative.
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch
LENZ Therapeutics announced strong preliminary Q4 2025 results, reporting approximately $1.6 million in net product revenue for VIZZ, its presbyopia treatment. The company saw over 20,000 VIZZ prescriptions filled and highlighted rapid adoption by eyecare professionals, with over 6,500 unique prescribers. LENZ also secured a new commercialization partnership for VIZZ in the Middle East with Lunatus, representing its fourth international agreement.
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch
LENZ Therapeutics, Inc. announced preliminary unaudited financial results for Q4 2025, reporting approximately $1.6 million in VIZZ net product revenue following its FDA approval and launch. Over 20,000 VIZZ prescriptions were filled, with strong uptake from more than 6,500 eyecare professionals. The company also highlighted a new commercialization partnership for VIZZ in the Middle East with Lunatus, marking its fourth such agreement outside the U.S.
LENZ Therapeutics Reports Strong Initial Sales and Prescription Volume for VIZZ™ after Launch for Presbyopia Treatment
LENZ Therapeutics launched VIZZ™, the first aceclidine-based eye drop for presbyopia, in October 2025, generating $1.6 million in net revenue and over 20,000 prescriptions by the end of Q4 2025. Over 6,500 eye care professionals have prescribed VIZZ, with many doing so multiple times, demonstrating strong early market acceptance. The company plans a direct-to-consumer campaign with Sarah Jessica Parker and has expanded internationally with a partnership in the Middle East.
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
LENZ Therapeutics reported preliminary unaudited financial results for Q4 2025, announcing approximately $1.6 million in net product revenue with over 20,000 VIZZ™ eye drop prescriptions filled since its October 2025 launch. The company noted rapid uptake by eye care professionals, with over 6,500 unique prescribers, and also announced an exclusive commercialization partnership for VIZZ in the Middle East with Lunatus. A direct-to-consumer campaign for VIZZ featuring Sarah Jessica Parker is planned for the current quarter.
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
LENZ Therapeutics has partnered with Lunatus Marketing & Consulting FZCO for the exclusive commercialization of VIZZ™, an FDA-approved eye drop for presbyopia, in the Middle East. This agreement includes upfront and milestone payments to LENZ, along with a significant share of revenue. Lunatus will manage registration and sales in countries including the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq, expanding VIZZ's global access.
LENZ Therapeutics and Lunatus Ink Exclusive Commercialization Partnership for VIZZ in Middle East
LENZ Therapeutics has partnered with Lunatus to commercialize VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia treatment across the Middle East. Under this exclusive distribution agreement, LENZ will receive upfront, regulatory, and commercial milestone payments, plus a significant share of revenue. This expands LENZ's global reach for VIZZ, which received FDA approval in July 2025 and became commercially available in the U.S. in September 2025.
FDA-approved presbyopia eye drop VIZZ to reach Middle East
LENZ Therapeutics and Lunatus have entered an exclusive distribution agreement for VIZZ, an FDA-approved presbyopia eye drop, across nine Middle Eastern countries. LENZ will receive upfront, regulatory, and commercial milestone payments, plus a significant share of regional revenue from the deal. This partnership expands VIZZ's global reach, building on its FDA approval in July 2025 and U.S. commercial availability since September 30, 2025.
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
LENZ Therapeutics and Lunatus Marketing & Consulting FZCO have formed an exclusive distribution agreement for Lunatus to commercialize VIZZ TM, an FDA-approved eye drop for presbyopia, in the Middle East region. This partnership, which includes upfront, regulatory, and commercial milestone payments plus revenue sharing, aims to expand global access to VIZZ. Lunatus will hold exclusive commercialization rights across several Middle Eastern countries, leveraging its strong regional presence and expertise in ophthalmology.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (NASDAQ: LENZ) following a reported retinal tear associated with their VIZZ eye drop, which appeared in the FDA's adverse event reporting systems. This adverse event led to a significant drop in LENZ's stock price. Investors affected by the potential securities fraud or unlawful business practices are advised to contact the firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics, Inc. following a significant drop in its stock price. The investigation was initiated after a case of retinal tear associated with LENZ's VIZZ eye drop was reported in the FDA's adverse event systems, causing the stock to fall by over 25%. Investors are encouraged to contact the firm for more information regarding a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating LENZ Therapeutics, Inc. (NASDAQ: LENZ) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows a significant drop in LENZ's stock price after reports of a retinal tear associated with their VIZZ eye drop appeared in the FDA's adverse event reporting systems. Investors are encouraged to contact Pomerantz LLP for information about joining the class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics, Inc. following a significant drop in its stock price. This investigation was triggered after a retinal tear case associated with LENZ's VIZZ eye drop appeared in a Food and Drug Administration adverse event reporting system, causing LENZ's stock to fall by 25.96% on December 12, 2025. Investors are encouraged to contact the law firm for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential claims against LENZ Therapeutics, Inc. (NASDAQ:LENZ) following a significant stock price drop. The investigation stems from the appearance of a retinal tear case associated with LENZ's VIZZ eye drop in the FDA's adverse event reporting systems, leading to a 25.96% decrease in share price on December 12, 2025. Investors are encouraged to contact the law firm regarding their potential claims.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential claims against LENZ Therapeutics, Inc. (LENZ) following a significant drop in its stock price. The investigation stems from the appearance of a retinal tear associated with LENZ's VIZZ eye drop in the Food and Drug Administration's adverse event reporting system on or around December 12, 2025, which caused the stock to fall by over 25%. Investors who believe they have been affected are encouraged to contact the law firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP has initiated an investigation into LENZ Therapeutics, Inc. (NASDAQ:LENZ) concerning potential securities fraud or unlawful business practices. This follows a significant drop in LENZ's stock price after a reported case of retinal tear associated with their VIZZ eye drop appeared in the FDA's adverse event reporting systems. Investors affected by the stock price decline are encouraged to contact the law firm.
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.1% - Time to Sell?
LENZ Therapeutics (NASDAQ:LENZ) saw its stock price drop by 5.1% on Tuesday, trading at $16.73 with significantly lower volume. Despite a "Moderate Buy" consensus from analysts and recent earnings beats, the stock remains below its 50 and 200-day moving averages. Insider transactions showed mixed signals, with one insider selling shares and the CFO purchasing shares.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics, Inc. (NASDAQ:LENZ) after a case of retinal tear linked to its VIZZ eye drop appeared in the FDA's adverse event reporting systems. Following this disclosure, LENZ's stock price dropped by 25.96%. The law firm is advising affected investors to contact them regarding a possible class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics, Inc. following a significant drop in its stock price. The investigation stems from a reported retinal tear associated with LENZ's VIZZ eye drop, which appeared in an FDA adverse event reporting system, causing LENZ's stock to fall over 25%. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action lawsuit.
LENZ Therapeutics (NASDAQ:LENZ) Shares Up 5% - What's Next?
LENZ Therapeutics (NASDAQ:LENZ) saw its shares rise by 5% on Wednesday, trading at $17.53 with a significant increase in volume. Despite this gain, the stock remains below its 50- and 200-day moving averages and the average analyst price target of $56.40, though analyst sentiment is largely positive with a "Moderate Buy" consensus. The company recently beat quarterly estimates, and insider activity shows both buying from the CFO and selling from another insider, with institutional ownership around 54%.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Analysts
LENZ Therapeutics, Inc. (NASDAQ:LENZ) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $56.40. Recent insider buying by the CFO and a director, along with the company beating quarterly earnings expectations, are highlighted. Despite positive analyst sentiment and strong revenue, the stock is currently trading near its 12-month low, presenting a discrepancy between market performance and analyst outlook.
LENZ Therapeutics (NASDAQ:LENZ) Sees Large Volume Increase - Should You Buy?
LENZ Therapeutics (NASDAQ:LENZ) experienced a significant 221% increase in trading volume on Friday, with approximately 1.59 million shares traded and the stock closing at $19.33 after an earlier close of $24.50. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $56.40, following recent target increases from Piper Sandler and Raymond James. The company beat quarterly earnings and revenue estimates, and notable insider activity includes a director purchasing 10,500 shares.
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year Low - Should You Sell?
LENZ Therapeutics (NASDAQ:LENZ) recently hit a new 52-week low of $15.70, though analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $56.40. The company beat quarterly earnings and revenue estimates. Insider transactions show a director purchasing shares, while another insider sold shares.
LENZ stock tumbles after retinal tear case surfaces in FDA database
LENZ Therapeutics stock dropped 25% after a retinal tear case linked to its VIZZ eye drop appeared in the FDA's adverse event reporting system. The patient had a history of retinal disease, and the incidence rate of 0.01-0.02% aligns with the company's guidance for retinal tears. Investors are monitoring VIZZ's commercial trajectory amidst these safety concerns.
Here's Why We're Not At All Concerned With LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn Situation
LENZ Therapeutics (NASDAQ:LENZ) is not a concern regarding its cash burn situation. The company has a cash runway of about 4.4 years and analysts expect it to reach cashflow breakeven before then. Moreover, its cash burn has been reduced by 36% year-on-year, and its cash burn relative to its market capitalization is small, making it easy to raise more capital if needed.
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report
Lenz Therapeutics' stock dropped significantly due to a reported retinal tear adverse event related to its new product, VIZZ, although the company states the patient had a pre-existing condition and is recovering. This incident highlights sector-specific risks, as AbbVie Inc. (ABBV) has faced similar challenges with its ophthalmic product, Vuity. Despite these industry-wide issues, AbbVie maintains a strong market position with a diverse portfolio and healthy financials.
LENZ Therapeutics Addresses Adverse Event Report
LENZ Therapeutics addressed a report of a retinal tear linked to the use of VIZZ™ on December 12, 2025. The company stated the patient had pre-existing retinal conditions and the tear occurred on a non-dosing day, with independent specialists finding no clear causal link to VIZZ. LENZ Therapeutics maintains its current safety expectations for VIZZ.
Stempoint Capital LP Buys Shares of 183,912 LENZ Therapeutics, Inc. $LENZ
Stempoint Capital LP has acquired 183,912 shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) in Q2, making it a significant position in their portfolio. This move is part of broader institutional interest in LENZ, with several major funds increasing or initiating positions. Analysts maintain a "Moderate Buy" rating with an average target price of $56.40, following the company's better-than-expected Q2 earnings report.
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod
The article discusses the FDA approval of Vizz Eye Drop, a new treatment designed to improve near vision. This development could offer an alternative to reading glasses for individuals experiencing presbyopia.
Saturn V Capital Management LP Invests $10.03 Million in LENZ Therapeutics, Inc. $LENZ
Saturn V Capital Management LP has acquired a new stake of 342,312 shares in LENZ Therapeutics, Inc. valued at approximately $10.03 million, making it their 13th largest holding. Insiders have increased their exposure to LENZ Therapeutics, and institutional investors now hold about 54.32% of the stock. Analysts currently rate LENZ Therapeutics with a "Moderate Buy" consensus and an average price target of $56.40, following a recent beat on quarterly earnings estimates.
Lenz Therapeutics: A Close Look (NASDAQ:LENZ)
LENZ Therapeutics is currently rated HOLD due to the high dependency of its product VIZZ's commercial success on uncertain consumer behavior, rather than medical necessity. While VIZZ offers improved safety and tolerability over competitors, it faces the challenge of competing with inexpensive reading glasses, making revenue forecasting difficult. Insiders have recently purchased shares, and the current valuation reflects a base-case where VIZZ outperforms Vuity but not dramatically, necessitating more revenue data for confident investment.
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10
LENZ Therapeutics, Inc. presented at Citi's Annual Global Healthcare Conference on December 4, 2025. The presentation featured biotech analyst Yigal Nochomovitz from Citi. The full transcript of the presentation is restricted to subscribers.
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ
Skandinaviska Enskilda Banken AB publ has acquired a new stake of 93,280 shares in LENZ Therapeutics, Inc., valued at approximately $2.73 million, making institutional investors collectively own 54.32% of the company. LENZ Therapeutics reported a Q2 EPS of ($0.59), beating consensus estimates, and revenue of $12.5 million, significantly exceeding expectations. Despite insider selling by Shawn Olsson, Director James W. McCollum increased his holdings, and analysts maintain a "Moderate Buy" rating with an average target price of $56.40.
Geode Capital Management LLC Grows Stock Position in LENZ Therapeutics, Inc. $LENZ
Geode Capital Management LLC increased its stake in LENZ Therapeutics, Inc. by 15.5% in the second quarter, now holding 416,122 shares valued at approximately $12.2 million. Institutional investors collectively own 54.32% of the company's stock, while analysts maintain a "Moderate Buy" consensus with an average target price of $56.40. The biopharmaceutical company is advancing two Phase III candidates for presbyopia, LNZ100 and LNZ101.
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
LENZ Therapeutics and Lotus Pharmaceutical have submitted a New Drug Application (NDA) to South Korea's Ministry of Food and Drug Safety (MFDS) for VIZZ™ (aceclidine ophthalmic solution) 1.44%, targeting the treatment of presbyopia. This marks the second ex-U.S. regulatory submission for VIZZ, driven by positive Phase 3 CLARITY trial data showing rapid and long-lasting near vision improvement with good tolerability. The submission is a significant step towards global commercialization and expands Lotus Pharmaceutical's portfolio in key Asian markets.
